Categories: News

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021

BOSTON, April 22, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the first quarter ended March 31, 2021, and provide an update on recent business highlights, on May 6, 2021.

The Company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 5658628. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Cambridge, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com       

Staff

Recent Posts

Red Light Holland CTIO to Unveil Groundbreaking iMicroapp Research Findings to Prestigious Drug Science Consortium

Toronto, Ontario--(Newsfile Corp. - July 9, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE:…

2 hours ago

Hop on a Cure Makes Financial Contribution Toward ALS CURE Project

ATLANTA, GA / ACCESSWIRE / July 9, 2024 / Hop On A Cure, a leading…

2 hours ago

Ludwig Enterprises Files Provisional Patent on mRNA Genetic Screening Signals in Breast, Colon and Bladder Cancer

SPARKS, NV / ACCESSWIRE / July 9, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a…

2 hours ago

Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine

BOULDER, CO / ACCESSWIRE / July 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global…

2 hours ago

Aeroflow Health Announces its Family Forward NC Certification

As a Family Forward NC certified employer, Aeroflow Health is recognized as a business with…

2 hours ago